[HTML][HTML] Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
RA Larson, DW Kim, S Issaragrisil, PD Le Coutre… - Leukemia, 2016 - nature.com
Abstract In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials–Newly
Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates …
Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates …
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A Hochhaus, G Saglio, TP Hughes… - …, 2016 - mdanderson.elsevierpure.com
Abstract In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly
Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates …
Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates …
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A Hochhaus, G Saglio, TP Hughes, RA Larson… - Leukemia, 2016 - go.gale.com
In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed
Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates and a …
Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates and a …
[PDF][PDF] Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A Hochhaus, G Saglio, TP Hughes, RA Larson… - Leukemia, 2016 - baranpharmaco.ir
Nilotinib is a tyrosine kinase inhibitor (TKI) approved for the treatment of adult patients with
newly diagnosed Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia in …
newly diagnosed Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia in …
[PDF][PDF] Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A Hochhaus, G Saglio, TP Hughes, PE Dorlhiac-Llacer… - 2016 - researchgate.net
Abstract In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials–Newly
Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates …
Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates …
[引用][C] Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A Hochhaus, G Saglio, TP Hughes, RA Larson… - Leukemia, 2016 - cir.nii.ac.jp
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in
chronic phase: 5-year update of the randomized ENESTnd trial | CiNii Research CiNii 国立 …
chronic phase: 5-year update of the randomized ENESTnd trial | CiNii Research CiNii 国立 …
[PDF][PDF] Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A Hochhaus, G Saglio, TP Hughes, RA Larson… - Leukemia, 2016 - baranpharma.com
Nilotinib is a tyrosine kinase inhibitor (TKI) approved for the treatment of adult patients with
newly diagnosed Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia in …
newly diagnosed Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia in …
[HTML][HTML] Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A Hochhaus, G Saglio, TP Hughes, RA Larson… - Leukemia, 2016 - ncbi.nlm.nih.gov
Abstract In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials–Newly
Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates …
Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates …
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A Hochhaus, G Saglio, TP Hughes, RA Larson… - 2016 - pubmed.ncbi.nlm.nih.gov
In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed
Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates and a …
Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates and a …
[PDF][PDF] Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A Hochhaus, G Saglio, TP Hughes, RA Larson… - Leukemia, 2016 - academia.edu
Nilotinib is a tyrosine kinase inhibitor (TKI) approved for the treatment of adult patients with
newly diagnosed Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia in …
newly diagnosed Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia in …